Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Sponsor
Fudan University
Study ID
NCT04843943
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Sintilimab — DRUG
    Sintilimab: 200mg IV Q3W D1
  • Bevacizumab Biosimilar — DRUG
    Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1

Study Details

This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).

Key Dates

First listed
Apr 14, 2021
Start date
May 1, 2021
Status verified
Apr 2021
Primary completion
May 1, 2022
Completion
May 1, 2023

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sintilimab+Bevacizumab

Primary Outcome Measure

Adverse Events (AEs) [ Time Frame: Up to 2 years ]

Central Contacts

Related Studies